Browse All Opioids Market Research Reports
List of reports from Opioid
Displaying 1 to 9 (of 9 records)
| Pages: « Last 1 |
|
Opium (Opioid) Addiction Pipeline Review, H1 2013
Mar 2013 | By - Global Markets Direct
Opium (Opioid) Addiction Pipeline Review, H1 2013
Summary
Global Markets Directs, 'Opium (Opioid) Addiction Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Opium (Opioid) Addiction, complete with latest updates, and special features on late-stage and...
|
$2000 |
|
Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market
Jan 2013 | By - GBI Research
Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market
Summary
Leading business intelligence provider GBI Research has released its latest research report, entitled “Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in...
|
$3500 |
|
Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2012
Dec 2012 | By - Global Markets Direct
Opioid-Induced Constipation (OIC) Pipeline Review, H2 2012
Summary
Global Markets Directs, 'Opioid-Induced Constipation (OIC) Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Opioid-Induced Constipation (OIC), complete with latest updates, and special...
|
$2000 |
|
Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2012
Nov 2012 | By - GlobalData
Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2012
Summary
GlobalData's clinical trial report, Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2012" provides data on the Opium (Opioid) Addiction clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Opium (Opioid) Addiction. It...
|
$2500 |
|
Opium (Opioid) Addiction - Pipeline Review, H2 2012
Sep 2012 | By - Global Markets Direct
Opium (Opioid) Addiction - Pipeline Review, H2 2012 Summary Global Markets Directs, 'Opium (Opioid) Addiction - Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Opium (Opioid) Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also...
|
$2000 |
|
Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities
Aug 2012 | By - GBI Research
GBI Research, leading business intelligence provider has released its latest research report, entitled Substance Abuse Therapeutics Market to 2018 Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities. The report provides insights into the substance abuse therapeutics market including market forecasts up to 2018. It provides an...
|
$3500 |
|
Prescribing Trends in Opioids - Driven by Efficacy Advantages, Opioids to Remain the Mainstay of Breakthrough Pain Management
May 2012 | By - GBI Research
GBI Research, the leading business intelligence provider, has released its latest research, Prescribing Trends in Opioids Driven by Efficacy Advantages, Opioids to Remain the Mainstay of Breakthrough Pain Management, provides in-depth analysis of unmet needs, drivers and barriers that impact the opioids market. The report analyzes current method of practice for various indications...
|
$3500 |
|
Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market
Jun 2011 | By - GBI Research
GBI Research, the leading business intelligence provider, has released its latest research, Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market, which provides insights into global opioids market and market forecast until 2017. The report provides an in-depth analysis of the top seven therapeutic indications for...
|
$3500 |
|
Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS
May 2011 | By - GBI Research
GBI Research's research, Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS, provides key data, information and analysis on the risk management and mitigation strategies, mandated by the FDA and being implemented by pharmaceutical companies. The report provides information on the...
|
$3500 |
Displaying 1 to 9 (of 9 records)
| Pages: « Last 1 |
Research Assistance
We will be happy to help you find what you need.
Please call us or write us:
Please call us or write us:
866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Email: sales@researchmoz.com
